|
|
|
|
|
27.02.26 - 22:33
|
FRO – Changes to the Board Composition (GlobeNewswire EN)
|
|
|
Frontline plc (“Frontline” or the “Company”) announces that Mr. Ørjan Svanevik has resigned as Director of the Company. The Board would like to thank Mr. Svanevik for his considerable contribution to the Company during his directorship....
|
|
|
27.02.26 - 22:33
|
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision....
|
|
|
|
|
27.02.26 - 22:30
|
FEMSA Announces Date for Shareholders′ Meetings and Dividend Payment Proposal (GlobeNewswire EN)
|
|
|
MONTERREY, Mexico, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) announced that it will hold its Annual Ordinary Shareholders' Meeting, as well as an Extraordinary Shareholders' Meeting on March 27, 2026, in Monterrey, Nuevo Leon, Mexico (the “Shareholders' Meetings”). The formal notice will be available in the following link in the coming days: https://femsa.gcs-web.com/shareholder-meeting-information....
|
|
|
|
|
|
|
27.02.26 - 22:18
|
NanoXplore Corporate Announcement (GlobeNewswire EN)
|
|
|
MONTREAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NanoXplore Inc. (“NanoXplore” or “the Corporation”) (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, announced today the mutually agreed resignation of Soroush Nazarpour from its Board of Directors. The Corporation reaffirmed that it remains fully focused on executing its strategic priorities and advancing its graphene growth initiatives....
|
|
|
|
|
|
|
|
|
27.02.26 - 22:18
|
Microchip Technology to Present at the Raymond James Institutional Investors Conference (GlobeNewswire EN)
|
|
|
CHANDLER, Ariz., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Raymond James Institutional Investors Conference on Monday, March 2, 2026 at 1:05 p.m. (Eastern Time). Presenting for the Company will be Mr. Sajid Daudi, Head of Investor Relations. A live webcast of the presentation will be made available by Raymond James, and can be accessed on the Microchip website at www.microchip.com....
|
|
|
27.02.26 - 22:18
|
Fold Eliminates its Convertible Debt; Emerges with Simplified Capital Structure and Strengthened Balance Sheet to Accelerate Growth (GlobeNewswire EN)
|
|
|
PHOENIX, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Fold Holdings, Inc. (NASDAQ: FLD) (“Fold” or the “Company”), a bitcoin financial services company making it easy for individuals to earn, save, and spend bitcoin through everyday financial tools, today announced the successful execution of a series of strategic capital transactions designed to bolster its financial flexibility, simplify its balance sheet, and position the company for its next phase of growth, including the anticipated launch and scaling of the Fold Credit Card....
|
|
|
27.02.26 - 22:18
|
Microchip Technology to Present at the Morgan Stanley Technology, Media & Telecom Conference (GlobeNewswire EN)
|
|
|
CHANDLER, Ariz., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Morgan Stanley Technology, Media & Telecom Conference on Tuesday March 3, 2026 at 1:05 p.m. (Pacific Time). Presenting for the Company will be Mr. Richard Simoncic, Chief Operating Officer, and Mr. Eric Bjornholt, Senior Vice President and Chief Financial Officer. A live webcast of the presentation will be made available by Morgan Stanley, and can be accessed on the Microchip website at www.microchip.com....
|
|
|
|
|
27.02.26 - 22:15
|
Methode Electronics Announces Third Quarter Fiscal 2026 Results Conference Call (GlobeNewswire EN)
|
|
|
SOUTHFIELD, Mich., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, announced it will conduct a conference call and webcast on Friday, March 6, 2026, at 11:00 a.m. EST to review its third quarter fiscal 2026 results. President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik will lead the call....
|
|
|
|
|
27.02.26 - 22:12
|
Draganfly Announces Closing of US$50.0 Million Registered Direct Offering (GlobeNewswire EN)
|
|
|
Saskatoon, SK., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the closing of its previously announced registered direct offering of 7,150,000 common shares (or pre-funded warrants in lieu thereof) of the Company at a price of US$7.00, for gross proceeds of approximately US$50.0 million, before deducting placement agent discounts and offering expenses (the “Offering”)....
|
|
|
27.02.26 - 22:06
|
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome (GlobeNewswire EN)
|
|
|
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS)....
|
|
|
|